Is response to antiviral treatment influenced by hepatitis B virus genotype?

Journal of Hepatology

Volumn 52, Issue 3, 2010, Pages 441-449

  Raimondi, Sara ^a   Maisonneuve, Patrick ^a   Bruno, Savino ^b   Mondelli, Mario U ^c  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b FATEBENEFRATELLI HOSPITAL   (Italy)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Antiviral treatment; Genotype; Hepatitis B virus

Indexed keywords

ADEFOVIR DIPIVOXIL; ENTECAVIR; LAMIVUDINE; NUCLEOSIDE ANALOG; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; TELBIVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL;

ADJUVANT THERAPY; ANTIVIRAL THERAPY; CLINICAL FEATURE; CLINICAL TRIAL; FALSE POSITIVE RESULT; GENE INTERACTION; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INFORMATION RETRIEVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; STATISTICS; TREATMENT INDICATION; TREATMENT RESPONSE;

ANTIVIRAL AGENTS; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; INTERFERON ALFA-2B; LAMIVUDINE; POLYETHYLENE GLYCOLS; TREATMENT OUTCOME;

EID: 77249123832     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2009.12.014     Document Type: Review

References (37)

1. Fattovich G., Bortolotti F., and Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 48 (2008) 335-352
2. Liang T.J. Hepatitis B: the virus and the disease. Hepatology 49 Suppl. (2009) S13-S21
3. Ghany M.G., Strader D.B., Thomas D.L., and Seeff L.B. Diagnosis, management and treatment of hepatitis C: an update. Hepatology 49 (2009) 1335-1374
4. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 50 (2009) 227-242
5. Chu C.J., and Lok A.S. Clinical significance of hepatitis B virus genotypes. Hepatology 35 (2002) 1274-1276
6. In: Mason W.S., Burrell C.J., Casey J., Gerlich W.H., Howard C.R., Kann M., et al. (Eds). Virus taxonomy. Eighth report of the international committee on taxonomy of viruses (2005), Elsevier, Amsterdam
7. Schaefer S. Hepatitis B virus taxonomy and hepatitis B virus genotypes. World J Gastroenterol 13 (2007) 14-21
8. Hannoun C., Krogsgaard K., Horal P., and Lindh M. Group tIT. Genotype mixtures of hepatitis B virus in patients treated with interferon. J Infect Dis 186 (2002) 752-759
9. Kao J.H., Chen P.J., Lai M.Y., and Chen D.S. Acute exacerbations of chronic hepatitis B are rarely associated with superinfection of hepatitis B virus. Hepatology 34 (2001) 817-823
10. Sugauchi F., Orito E., Ichida T., Kato H., Sakugawa H., Kakumu S., et al. Hepatitis B virus of genotype B with or without recombination with genotype C over the precore region plus the core gene. J Virol 76 (2002) 5985-5992
11. Kao J.H., Chen P.J., Lai M.Y., and Chen D.S. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 118 (2000) 554-559
12. Fujie H., Moriya K., Shintani Y., Yotsuyanagi H., Iino S., and Koike K. Hepatitis B virus genotypes and hepatocellular carcinoma in Japan. Gastroenterology 120 (2001) 1564-1565
13. Taylor B.C., Yuan J.-M., Shamliyan T.A., Shaukat A., Kane R.L., and Wilt T.J. Clinical outcomes in adults with chronic hepatitis B in association with patient and viral characteristics: a systematic review of evidence. Hepatology 49 (2009) S85-S95
14. Yu M.W., Yeh S.H., Chen P.J., LiawY F., Lin C.L., Liu C.J., et al. Genotype and DNA levels of hepatitis B virus and the risk of hepatocellular carcinoma. J Natl Cancer Inst 97 (2005) 265-272
15. Livingston S.E., Simonetti J.P., McMahon B.J., Bulkow L.R., Hurlburt K.J., Homan C.E., et al. Hepatitis B virus genotypes in Alaska Native people with hepatocellular carcinoma: preponderance of genotype F. J Infect Dis 195 (2007) 5-11
16. Sorrell M.F., Belongia E.A., Costa J., Gareen I.F., Grem J.L., and Inadomi J.M. National Institutes of Health consensus development conference statement: management of hepatitis B. Hepatology 49 (2009) S4-S12
17. Flink H.J., van Zonneveld M., Hansen B.E., de Man R.A., Schalm S.W., and Janssen H.L.A. Treatment with Peg-interferon α-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am J Gastroenterol 101 (2006) 297-303
18. Buster E.H.C.J., Flink H.J., Cakaloglu Y., Simon K., Trojan J., Tabak F., et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon α-2b. Gastroenterology 135 (2008) 459-467
19. Wiegand J., Hasenclever D., and Tillmann H.L. Should treatment of hepatitis B depend on hepatitis B virus genotypes? A hypothesis generated from the explorative analysis of published evidence. Antivir Ther 13 (2008) 211-220
20. Erhardt A., Ludwig A.D., Brunetto M., van Boemmel F., Wolf E., Goebel T., et al. HBV genotypes are the strongest predictors of response to interferon-alfa treatment: multivariate evaluation in 1229 hepatitis B patients [Abstract]. Hepatology 48 Suppl. (2008) 700A
21. Hou J., Schilling R., Janssen H.L.A., Hansen B.E., Heijtink R., Sablon E., et al. Genetic characteristics of hepatitis B virus genotypes as a factor for interferon-induced HBeAg clearance. J Med Virol 79 (2007) 1055-1063
22. Pantaleo G., and Harari A. Functional signatures in antiviral T-cell immunity for monitoring virus-associated diseases. Nat Rev Immunol 6 (2006) 417-423
23. Lai C.L., Gane E., Liaw Y.F., Hsu C.W., Thongsawat S., Wang Y., et al. Globe Study Group. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 357 (2007) 2576-2588
24. Hou J., Yin Y.K., Xu D., Tan D., Niu J., Zhou X., et al. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: results at 1 year of a randomized, double-blind trial. Hepatology 47 (2008) 447-454
25. Marcellin P., Heathcote E.J., Buti M., Gane E., de Man R.A., Krastev Z., et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 359 (2008) 2442-2455
26. Schiff E., Simsek H., Lee W.M., Chao Y.C., Sette Jr. H., Janssen H.L., et al. Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis. Am J Gastroenterol 103 (2008) 2776-2783
27. Westland C., Delaney IV W., Yang H., Chen S.S., Marcellin P., Hadziyannis S., et al. Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil. Gastroenterology 125 (2003) 107-116
28. Buster E.H., Hansen B.E., Buti M., Delwaide J., Niederau C., Michielsen P.P., et al. HBV 99-01 Study Group. Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis. Hepatology 46 (2007) 388-394
29. Lau G.K., Piratvisuth T., Luo K.X., Marcellin P., Thongsawat S., Cooksley G., et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group. N Engl J Med 352 (2005) 2682-2695
30. Zeuzem S., Gane E., Liaw Y.F., Lim S.G., DiBisceglie A., Buti M., et al. Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. J Hepatol 51 (2009) 11-20
31. Zhao H., Kurbanov F., Wan M.B., Yin Y.K., Niu J.Q., Hou J.L., et al. Genotype B and younger patient age associated with better response to low-dose therapy: a trial with pegylated/nonpegylated interferon-alpha-2b for hepatitis B e antigen-positive patients with chronic hepatitis B in China. Clin Infect Dis 44 (2007) 541-548
32. Janssen H.L., van Zonneveld M., Senturk H., Zeuzem S., Akarca U.S., Cakaloglu Y., et al. HBV 99-01 Study Group. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 365 (2005) 123-129
33. Bonino F., Marcellin P., Lau G.K., Hadziyannis S., Jin R., Piratvisuth T., et al. Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut 56 (2007) 699-705
34. Liaw Y.F., Gane E., Leung N., Zeuzem S., Wang Y., Lai C.L., et al. GLOBE Study Group. 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 136 (2009) 486-495
35. Sherman M., Yurdaydin C., Simsek H., Silva M., Liaw Y.F., Rustgi V.K., et al. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology 48 (2008) 99-108
36. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., Chang T.T., Kitis G., Rizzetto M., et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 131 6 (2006) 1743-1751
37. Moucari R., Korevaar A., Lada O., Martinot-Peignoux M., Boyer N., Mackiewicz V., et al. High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study. J Hepatol 50 (2009) 1084-1092